方法：选择我科2009-01/2010-12经眼底血管造影(fundus fluorescein angiography，FFA)、光学相干断层扫描(optical coherence tomography，OCT)确诊存在黄斑中心凹下CNV的患者60例60眼作为观察对象。玻璃体腔内注射Avastin 1.25mg，每6wk注射一次。记录治疗后1，2，3d； 3wk； 3，6mo BCVA、眼压、晶状体、玻璃体的变化，观察脉络膜渗漏情况和黄斑中心凹视网膜厚度(central foveal thickness，CFT)，进行比较。

结果：患者共60例，其中男26例26眼，女34例34眼，平均年龄62岁。治疗前患者的基线平均对数BCVA为logMAR 1.15±0.41，CFT为395.92± 94.39μm。注药后第1d BCVA有明显提高(logMAR 0.86±0.43)，1wk后CFT也有明显改善332.50± 68.35μm，经平均6mo的随访，BCVA(logMAR 0.71±0.37)，CFT(250.23±35.33μm)，两项指标均较基线有显著改善。本组患者共接受了113次玻璃体腔内注射，平均注射次数为1.88次/眼。治疗过程中未发现严重不良反应。

结论：玻璃体腔内注射Avastin治疗湿性AMD引起的CNV安全、副作用少，可改善患者的视功能，减轻黄斑水肿，减少CNV渗漏。

METHODS: Totally 60 patients(60 eyes)which were diagnosed by fundus fluorescein angiography(FFA)and indocyanine green angiography(ICGA)from January 2009 to December 2010. Sixty patients(60 eyes)with subfoveal CNV due to AMD participated in this study. An intravitreal injection of Avastin(1.25mg)was given at baseline and followed by two additional injections of six weeks intervals. The best-corrected visual acuity(BCVA), intraocular pressure, the change of lens and vitreous, choroidal leaks by indocyanine green angiography, and central retinal thickness by optical coherence tomography were observed 1 day, 2 days, 3 days, 3 weeks, 3 months and 6 months after the treatment and then compared.

RESULTS: Sixty eyes of 60 patients \〖26 males(26 eyes)and 34 females(34 eyes)\〗 with the average of 62 years old were included. The mean baseline of BCVA and central foveal thickness(CFT)were 1.15±0.41(logMAR), 395.92±94.39μm, respectively. The mean BCVA had significant improvement(logMAR 0.86±0.43)one day after the injection. The mean baseline of CFT also had significant decrease one week after the injection(332.50±68.35μm). At the last of 6 months follow-up, BCVA(logMAR 0.71±0.37), CFT(250.23±35.33μm)showed significant improvements over baseline values. A total of 113 injections were performed and the average number of injections was 1.88 in the group. There was no serious complication during the treatment.

CONCLUSION: Intravitreal Avastin for managing CNV due to age-related macular degeneration is safe and few side-effects. Intravitreal Avastin associated with improvement in VA, which can reduce macular edema and choroidal leakage.